Notice: This company has been marked as potentially delisted and may not be actively trading. ContraVir Pharmaceuticals (CTRV) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends CTRV vs. ZVSA, ALLR, DRMA, CYTO, OGEN, TRVN, SXTP, CWBR, EVFM, and REVBShould you be buying ContraVir Pharmaceuticals stock or one of its competitors? The main competitors of ContraVir Pharmaceuticals include ZyVersa Therapeutics (ZVSA), Allarity Therapeutics (ALLR), Dermata Therapeutics (DRMA), Altamira Therapeutics (CYTO), Oragenics (OGEN), Trevena (TRVN), 60 Degrees Pharmaceuticals (SXTP), CohBar (CWBR), Evofem Biosciences (EVFM), and Revelation Biosciences (REVB). These companies are all part of the "medical" sector. ContraVir Pharmaceuticals vs. ZyVersa Therapeutics Allarity Therapeutics Dermata Therapeutics Altamira Therapeutics Oragenics Trevena 60 Degrees Pharmaceuticals CohBar Evofem Biosciences Revelation Biosciences ContraVir Pharmaceuticals (NASDAQ:CTRV) and ZyVersa Therapeutics (NASDAQ:ZVSA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, community ranking, earnings, media sentiment, analyst recommendations and profitability. Which has better earnings & valuation, CTRV or ZVSA? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioContraVir PharmaceuticalsN/AN/A-$9.45MN/AN/AZyVersa TherapeuticsN/AN/A-$98.30MN/AN/A Do analysts prefer CTRV or ZVSA? ZyVersa Therapeutics has a consensus target price of $120.00, suggesting a potential upside of 6,182.72%. Given ZyVersa Therapeutics' higher probable upside, analysts plainly believe ZyVersa Therapeutics is more favorable than ContraVir Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ContraVir Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AZyVersa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is CTRV or ZVSA more profitable? ZyVersa Therapeutics' return on equity of -172.50% beat ContraVir Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets ContraVir PharmaceuticalsN/A -4,810.77% -130.14% ZyVersa Therapeutics N/A -172.50%-90.88% Does the media favor CTRV or ZVSA? In the previous week, ZyVersa Therapeutics had 4 more articles in the media than ContraVir Pharmaceuticals. MarketBeat recorded 4 mentions for ZyVersa Therapeutics and 0 mentions for ContraVir Pharmaceuticals. ZyVersa Therapeutics' average media sentiment score of 0.40 beat ContraVir Pharmaceuticals' score of 0.00 indicating that ZyVersa Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment ContraVir Pharmaceuticals Neutral ZyVersa Therapeutics Neutral Does the MarketBeat Community prefer CTRV or ZVSA? ContraVir Pharmaceuticals received 216 more outperform votes than ZyVersa Therapeutics when rated by MarketBeat users. However, 100.00% of users gave ZyVersa Therapeutics an outperform vote while only 74.49% of users gave ContraVir Pharmaceuticals an outperform vote. CompanyUnderperformOutperformContraVir PharmaceuticalsOutperform Votes21974.49% Underperform Votes7525.51% ZyVersa TherapeuticsOutperform Votes3100.00% Underperform VotesNo Votes Do institutionals & insiders have more ownership in CTRV or ZVSA? 1.1% of ContraVir Pharmaceuticals shares are owned by institutional investors. Comparatively, 3.9% of ZyVersa Therapeutics shares are owned by institutional investors. 1.6% of ContraVir Pharmaceuticals shares are owned by insiders. Comparatively, 0.6% of ZyVersa Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, CTRV or ZVSA? ContraVir Pharmaceuticals has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500. Comparatively, ZyVersa Therapeutics has a beta of 0.65, suggesting that its share price is 35% less volatile than the S&P 500. SummaryZyVersa Therapeutics beats ContraVir Pharmaceuticals on 8 of the 12 factors compared between the two stocks. Ad Porter & CompanyNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. Here’s the full story for you. Get ContraVir Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTRV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTRV vs. The Competition Export to ExcelMetricContraVir PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$520,000.00$7.02B$5.40B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E RatioN/A9.74115.4815.20Price / SalesN/A381.431,483.2092.69Price / CashN/A47.3339.6534.06Price / Book0.815.324.665.02Net Income-$9.45M$153.56M$119.06M$225.46M ContraVir Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTRVContraVir PharmaceuticalsN/A$0.65-1.5%N/A-85.2%$520,000.00N/A0.0014Gap DownZVSAZyVersa Therapeutics2.9091 of 5 stars$1.91-5.0%$120.00+6,182.7%-93.9%$1.97MN/A0.002ALLRAllarity Therapeutics0.731 of 5 stars$1.38-1.4%N/A-99.6%$1.95MN/A0.005DRMADermata Therapeutics2.1907 of 5 stars$1.23-3.2%$6.00+389.8%-86.2%$1.85MN/A-0.058Gap UpCYTOAltamira TherapeuticsN/A$0.50+4.2%N/A-83.9%$1.70M$320,000.000.0020OGENOragenicsN/A$0.30-3.3%N/AN/A$1.66M$40,000.00-0.045TRVNTrevena1.3684 of 5 stars$1.75-9.8%$125.00+7,042.9%-87.1%$1.51M$3.12M-0.0340Gap UpSXTP60 Degrees Pharmaceuticals3.1671 of 5 stars$0.78+1.3%N/A+28.1%$1.46M$250,000.008.533Positive NewsGap UpCWBRCohBarN/A$0.49flatN/A-46.7%$1.43MN/A0.0010EVFMEvofem Biosciences0.7861 of 5 stars$0.01flatN/A-80.7%$1.42M$18.22M-0.03120News CoverageREVBRevelation Biosciences0.8693 of 5 stars$0.82-3.5%N/A-95.5%$1.35MN/A-0.0310 Related Companies and Tools Related Companies ZyVersa Therapeutics Competitors Allarity Therapeutics Competitors Dermata Therapeutics Competitors Altamira Therapeutics Competitors Oragenics Competitors Trevena Competitors 60 Degrees Pharmaceuticals Competitors CohBar Competitors Evofem Biosciences Competitors Revelation Biosciences Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CTRV) was last updated on 11/2/2024 by MarketBeat.com Staff From Our PartnersMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ContraVir Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share ContraVir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
